Bedrijfsoverzicht
Hologic, Inc. is a prominent entity within the healthcare sector, specifically operating in the specialized industry of medical instruments and supplies. The company focuses on the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products designed for women's health through early detection and treatment worldwide. Its operational scope is segmented into four distinct areas: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. As of the latest data, the company commands a substantial market capitalization of $16.97B, which positions it as a significant player in the global healthcare equipment landscape. This valuation is supported by a robust annual revenue of $4.13B and an extensive workforce comprising 7070 employees. The scale indicated by these figures suggests that Hologic has established a mature business model with deep market penetration, yet the market cap relative to its revenue implies that investors are pricing in future growth expectations beyond mere operational scale. The substantial employee base further reflects the complexity and breadth of its manufacturing and distribution networks required to support its diverse product portfolio.
Financiële gezondheid
The financial performance of Hologic, Inc. is characterized by a trailing twelve-month (TTM) revenue of $4.13B and a net income of $543.80M, while EBITDA stands at $1.35B. The gap between the $4.13B revenue and the $543.80M net income reveals a significant cost structure where operating expenses, taxes, and other deductions consume approximately 86.8% of total sales before reaching the bottom line. The company generates a free cash flow of $848.61M, which indicates strong financial flexibility allowing for potential capital expenditures, debt reduction, or strategic acquisitions without immediate reliance on external financing. Profitability analysis shows a gross margin of 60.4%, reflecting the high value of its specialized diagnostic and imaging systems relative to production costs. An operating margin of 23.0% demonstrates efficient management of overheads and operational expenses, while a profit margin of 13.2% confirms the company's ability to convert sales into actual shareholder value after all costs. Regarding liquidity and leverage, the company holds $2.37B in cash against $2.52B in debt, resulting in a debt-to-equity ratio of 48.05%, which suggests a moderately leveraged balance sheet where equity capital significantly offsets debt obligations. Short-term liquidity is robust, evidenced by a current ratio of 4.04, indicating that the company possesses more than four times the current assets necessary to cover its current liabilities. Management effectiveness is further highlighted by a return on equity of 10.9% and a return on assets of 7.4%, metrics that show the company generates solid returns on both the shareholders' capital and the total asset base utilized.
Waarderingsbeoordeling
Valuation metrics for Hologic, Inc. present a mixed picture of historical performance versus future expectations, with a P/E ratio (TTM) of 31.54 compared to a forward P/E of 15.64. The substantial difference between the trailing and forward multiples implies that the market anticipates a significant improvement in earnings trajectory or a re-rating of the stock to align with lower current multiple standards. The price-to-book ratio stands at 3.23, indicating that the market prices the company at a premium of over three times its net book value, suggesting confidence in the intangible assets and future cash generation capabilities beyond tangible book value. Alternative valuation metrics such as a price-to-sales ratio of 4.11 and an EV/EBITDA of 12.68 provide context for the stock's price relative to its sales volume and earnings power before interest, taxes, depreciation, and amortization. Price volatility relative to the broader market is measured by a beta of 0.70, suggesting that the stock is less volatile than the overall market and may offer a defensive characteristic during periods of market turbulence. The 52-week trading range spans from a low of $51.90 to a high of $76.07, providing a clear band within which the current share price fluctuates. Without the current share price explicitly provided in the source facts, the valuation assessment relies on the established range where the stock has demonstrated resilience between these two price points over the past year.
Growth & Income
The growth dynamics of the company show a revenue growth of 2.5% year-over-year contrasted with an earnings growth of -9.2% year-over-year. This divergence indicates that earnings are currently growing slower than revenue, implying that cost pressures, margin compression, or one-time expenses are outweighing the benefits of top-line expansion. Hologic, Inc. does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company reinvests all of its earnings back into the business for research, development, and expansion rather than distributing cash to shareholders. The overall growth and income profile is defined by a focus on organic expansion and capital allocation for innovation rather than income generation through dividends. The negative earnings growth despite positive revenue highlights the importance of monitoring expense discipline in the current economic environment. The company's strategy prioritizes long-term market share growth and technological advancement in the women's health sector over immediate income distribution to investors.